COMPOUNDS AND USES THEREOF

1 . A compound having the structure of Formula I:

A-L-B   Formula I,

wherein

A is

wherein

A 1 is a bond between A and L;

R 4 is H, optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 1 -C 6 heteroalkyl, or optionally substituted C 3 -C 10 carbocyclyl

R 5 is H, halogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3 -C 10 carbocyclyl, or optionally substituted C 6 -C 10 aryl;

R 6a is H, halogen, cyano, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 2 -C 9 heterocyclyl, optionally substituted C 6 -C 10 aryl, optionally substituted C 2 -C 9 heteroaryl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 heteroalkenyl, hydroxy, thiol, or optionally substituted amino;

R 6b is H, halogen, cyano, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 2 -C 9 heterocyclyl, optionally substituted C 6 -C 10 aryl, optionally substituted C 2 -C 9 heteroaryl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 heteroalkenyl, hydroxy, thiol, or optionally substituted amino, or R 6a and R 6b , together with the carbon atoms to which each is attached, combine to form optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 9 heteroaryl;

B is

wherein

A 2 is a bond between B and L;

v1 is 0, 1, 2, 3, 4, or 5;

R A5 is H, optionally substituted C 1 -C 5 alkyl, or optionally substituted C 1 -C 5 heteroalkyl;

each R J1 is, independently, halogen, optionally substituted C 1 -C 6 alkyl, or optionally substituted C 1 -C 6 heteroalkyl;

J A is absent, O, optionally substituted amino, optionally substituted C 1 -C 5 alkyl, or optionally substituted C 1 -C 6 heteroalkyl; and

J is absent, optionally substituted C 3 -C 10 carbocyclylene, optionally substituted C 6 -C 10 arylene, optionally substituted C 2 -C 9 heterocyclylene, or optionally substituted C 2 -C 9 heteroarylene, optionally substituted amino, optionally substituted C 1 -C 6 alkyl, or optionally substituted C 1 -C 6 heteroalkyl; and

L is

A 1 -(E 1 )-(F 1 )—(C 3 ) m -(F 2 ) o1 -A 2 ,   Formula IId

wherein

A 1 is a bond between L and A;

A 2 is a bond between B and L;

each of m and o1 is, independently, 0 or 1;

O, S, NR N , optionally substituted C 1-10 alkylene, optionally substituted C 2-10 alkenylene, optionally substituted C 2-10 alkynylene, optionally substituted C 2 -C 10 polyethylene glycol, or optionally substituted C 1-10 heteroalkylene;

R N is H, optionally substituted C 1-4 alkyl, optionally substituted C 2-4 alkenyl, optionally substituted C 2-4 alkynyl, optionally substituted C 2-6 heterocyclyl, optionally substituted C 6-12 aryl, or optionally substituted C 1-7 heteroalkyl;

C 3 is carbonyl, thiocarbonyl, sulphonyl, or phosphoryl; and

each of F 1 and F 2 is, independently, optionally substituted C 3 -C 10 carbocyclylene, optionally substituted C 2-10 heterocyclylene, optionally substituted C 6 -C 10 arylene, or optionally substituted C 2 -C 9 heteroarylene,

or a pharmaceutically acceptable salt thereof.

2 - 17 . (canceled)

18 . The compound of claim 1 , wherein E 1 is

where a is 0, 1, 2, 3, 4, or 5.

19 . (canceled)

20 . The compound of claim 18 , wherein E 1 is

21 - 30 . (canceled)

31 . The compound of claim 1 , wherein each of F 1 and F 2 is, independently, optionally substituted C 3 -C 10 carbocyclylene.

32 - 38 . (canceled)

39 . The compound of claim 1 , wherein each of F 1 and F 2 is, independently, optionally substituted C 2 -C 6 heterocyclylene.

40 . (canceled)

41 . The compound of claim 39 , wherein the C 2 -C 6 heterocyclylene is

wherein

q1 is 0, 1, 2, 3, or 4;

q2 is 0, 1, 2, 3, 4, 5, or 6;

q3 is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

each Rh is, independently, 2 H, halogen, optionally substituted C 1 -C 6 alkyl, OR i2 , or NR i3 R i4 ; or two R h groups, together with the carbon atom to which each is attached, combine to form optionally substituted C 3 -C 10 carbocyclyl or optionally substituted C 2 -C 9 heterocyclyl; or two Rh groups, together with the carbon atoms to which each is attached, combine to form optionally substituted C 3 -C 10 carbocyclyl or optionally substituted C 2 -C 9 heterocyclyl;

R i1 is H or optionally substituted C 1 -C 6 alkyl;

R i2 is H, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, or optionally substituted C 3 -C 6 carbocyclyl;

42 - 50 . (canceled)

51 . The compound of claim 39 , wherein each of F 1 and F 2 is, independently,

52 . The compound of claim 39 , wherein F 1 is

53 . The compound of claim 39 , wherein F 2 is

54 - 77 . (canceled)

78 . The compound of claim 1 , wherein m is 0.

79 - 80 . (canceled)

81 . The compound of claim 1 , wherein o1 is 1.

82 - 116 . (canceled)

117 . The compound of claim 1 , wherein v1 is 0.

118 - 119 . (canceled)

120 . The compound of claim 1 , wherein R A5 is H.

121 - 128 . (canceled)

129 . The compound of claim 1 , wherein J is optionally substituted C 3 -C 10 carbocyclylene or optionally substituted C 6 -C 10 arylene.

130 - 186 . (canceled)

187 . The compound of claim 1 , wherein R 4 is H.

188 - 199 . (canceled)

200 . The compound of claim 1 , wherein R 5 is H,

201 . The compound of claim 200 , wherein R 5 is H or

202 - 204 . (canceled)

205 . The compound of claim 1 , wherein R 8a is H, F, cyano,

206 - 208 . (canceled)

209 . The compound of claim 1 , wherein R 6b is H, F, cyano,

210 - 300 . (canceled)

301 . A compound having the structure of any one of compounds D1-D259 in Table 1A, D260-D371 in Table 1B, D372-D476 in Table 1D, DD1-DD10 in Table 1C, and DD11-DD16 in Table 1E.

302 - 305 . (canceled)

306 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

307 . A method of inhibiting the level or activity of BRD9 in a cell, the method involving contacting the cell with an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

308 . (canceled)

309 . The method of claim 307 , wherein the cell is a cancer cell.

310 . The method of claim 309 , wherein the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, a sarcoma, non-small cell lung cancer, stomach cancer, or breast cancer.

311 . The method of claim 310 , wherein the cancer is a sarcoma.

312 . (canceled)

313 . The method of claim 311 , wherein the sarcoma is synovial sarcoma.

314 . A method of treating a BAF complex-related disorder, an SS18-SSX fusion protein-related disorder, or a BRD9-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

315 - 317 . (canceled)

318 . A method of treating a cancer in a subject in need thereof, the method including administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

319 . (canceled)

320 . The method of claim 318 , wherein the cancer is a sarcoma.

321 . (canceled)

322 . The method of claim 320 , wherein the sarcoma is synovial sarcoma.

323 . (canceled)

324 . A method of treating infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

325 - 327 . (canceled)

328 . The compound of claim 20 , wherein

each of R 4 , R 6a , and R 6b is

R 5 is H;

v1 is 0;

R A5 is H;

J A is amino;

J is optionally substituted C 6 -C 10 arylene;

m is 0;

o1 is 1;

F 1 is

and

F 2 is